


Ask a doctor about a prescription for IVABRADINE STADA 7.5 mg FILM-COATED TABLETS
Package Leaflet: Information for the Patient
Ivabradina Stada 7.5 mg Film-Coated Tablets EFG
Read the entire package leaflet carefully before starting to take this medication, as it contains important information for you.
Contents of the Package Leaflet:
Ivabradina is a heart medication used to treat:
About stable angina pectoris (commonly known as "angina")
Stable angina pectoris is a heart disease that occurs when the heart does not receive enough oxygen. It usually appears between the ages of 40 and 50. The most common symptom of angina is chest pain or discomfort. Angina is more likely to occur when the heart beats faster in situations such as exercise, emotion, exposure to cold, or after eating. This increase in heart rate can cause chest pain in people with angina.
About chronic heart failure:
Chronic heart failure is a heart disease that occurs when your heart cannot pump enough blood to the rest of your body. The most common symptoms of heart failure are difficulty breathing, fatigue, tiredness, and swelling of the ankles.
Ivabradina works mainly by reducing the heart rate by some beats per minute. This reduces the heart's need for oxygen, especially in situations where angina attacks are more likely to occur. In this way, Ivabradina tablets help control and reduce the number of angina attacks.
In addition, since a high heart rate negatively affects the functioning of the heart and vital prognosis in patients with chronic heart failure, the specific heart rate-lowering action of Ivabradina helps improve heart function and vital prognosis in these patients.
Do not take Ivabradina tablets
Warnings and precautions
Consult your doctor or pharmacist before starting to take Ivabradina tablets:
If you meet any of these conditions, consult your doctor immediately before or during treatment with Ivabradina tablets.
Children
Ivabradina tablets are not intended for use in children and adolescents under 18 years of age.
Using Ivabradina tablets with other medications
Tell your doctor or pharmacist if you are taking, have recently taken, or may need to take any other medication.
Make sure to inform your doctor if you are taking any of the following medications, as a dose adjustment of Ivabradina tablets or monitoring may be necessary:
Taking Ivabradina tablets with food and drinks
Avoid grapefruit juice during treatment with Ivabradina tablets.
Pregnancy and breastfeeding
Do not take Ivabradina tablets if you are pregnant or plan to become pregnant (see "Do not take Ivabradina tablets").
If you are pregnant and have taken Ivabradina tablets, consult your doctor.
Do not take Ivabradina tablets if you are of childbearing age and do not use reliable contraceptive methods (see "Do not take Ivabradina tablets").
Do not take Ivabradina tablets if you are breastfeeding (see "Do not take Ivabradina tablets"). Talk to your doctor if you are breastfeeding or plan to start breastfeeding, as breastfeeding should be discontinued if you are taking Ivabradina tablets.
If you are pregnant, breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.
Driving and using machines
Ivabradina tablets may cause transient visual phenomena (a transient brightness in the field of vision, see "Possible side effects"). If this happens, be careful when driving or using machinery in situations where sudden changes in light intensity may occur, especially when driving at night.
This medication contains lactose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medication.
This medication contains less than 23 mg of sodium (1 mmol) per tablet; this is, essentially "sodium-free".
Follow the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Ivabradina tablets should be taken with breakfast and dinner.
If you are being treated for stable angina pectoris
The initial dose should not exceed one 5 mg Ivabradina tablet twice a day. If you still have symptoms of angina and if you have tolerated the 5 mg dose twice a day, the dose can be increased. The maintenance dose should not exceed 7.5 mg twice a day. Your doctor will prescribe the correct dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g., if you are an elderly patient), your doctor may prescribe half the dose, i.e., half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of Ivabradina) in the morning and half a 5 mg tablet in the evening.
If you are being treated for chronic heart failure
The recommended initial dose is one 5 mg Ivabradina tablet twice a day, which can be increased if necessary to one 7.5 mg Ivabradina tablet twice a day. Your doctor will decide the suitable dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g., if you are an elderly patient), your doctor may prescribe half the dose, i.e., half a 5 mg Ivabradina tablet (corresponding to 2.5 mg of Ivabradina) in the morning and half a 5 mg tablet in the evening.
If you take more Ivabradina tablets than you should
An overdose of Ivabradina tablets can make you feel tired or have difficulty breathing because your heart is beating too slowly. If this happens, contact your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forget to take Ivabradina tablets
If you forget to take a dose of Ivabradina tablets, take the next dose at the scheduled time. Do not take a double dose to make up for the missed doses.
If you stop taking Ivabradina tablets
Generally, the treatment of angina pectoris or chronic heart failure is for life, so you should consult your doctor before stopping this medication.
If you think the action of Ivabradina tablets is too strong or too weak, inform your doctor or pharmacist.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them.
The most common adverse reactions with this medication are dose-dependent and related to its mechanism of action:
Very common side effects (may affect more than 1 in 10 people)
Transient visual phenomena (brief moments of increased brightness, usually caused by sudden changes in light intensity). They can also be described as a halo, flashes of color, image decomposition, or multiple images. These usually appear during the first two months of treatment, after which they may occur repeatedly and resolve during or after treatment.
Common side effects (may affect up to 1 in 10 people)
Modification of heart function (symptoms are a slowing of the heart rate). This occurs especially in the first 2 to 3 months after starting treatment.
Other side effects have also been reported:
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date stated on the packaging, after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through wastewater or household waste. Deposit the packaging and medications you no longer need at the SIGRE collection point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medications you no longer need. This will help protect the environment.
Ivabradina Stada 7.5 mg: one film-coated tablet contains 7.5 mg of ivabradina (equivalent to 8.085 mg of ivabradina as hydrochloride).
Ivabradina Stada 7.5 mg: film-coated tablets, round, pink, approximately 9.5 mm, marked with "I9VB" on one face and "7.5" on the other face.
The tablets are presented in PVC/PE/PVDC/Aluminum or Aluminum/Aluminum blister packs of 14, 28, 28 (sample), 56, 98, 100, or 112 film-coated tablets.
Only some pack sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Laboratory STADA, S.L.
Frederic Mompou, 5
08960 Sant Just Desvern (Barcelona) Spain
Manufacturer:
Synthon Hispania S.L.
C/Castelló nº1, Pol. Las Salinas
08830 Sant Boi de Llobregat (Barcelona)
Spain
or
Synthon BV
Microweg 22 Nijmegen
6545 CM
Netherlands
or
Synthon s.r.o.
Brnenská 32/cp. 597
678 01 Blansko
Czech Republic
or
STADA Arzneimittel AG
Stadastrasse 2 - 18,
61118 Bad Vilbel
Germany
or
STADA Arzneimittel GmbH
Muthgasse 36/2
1190 Vienna
Austria
or
Clonmel Healthcare Ltd.
Waterford Road
Clonmel, Co. Tipperary
Ireland
or
Centrafarm Services B.V.
Van de Reijtstraat 31-E4814 NE Breda Netherlands
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
AT Ivabradin Stada 7.5 mg Filmtabletten
DE Ivabradin AL 7.5 mg Filmtabletten
ES Ivabradina Stada 7.5 mg film-coated tablets EFG
FR IVABRADINE EG 7.5 mg, film-coated tablet
IT IVABRADINA EG
NL Ivabradine CF 7.5 mg, film-coated tablets
PT Ivabradina Ciclum
SI Ivabradin Stada 7.5 mg film-coated tablets
SK Ivabradín Stada 7.5 mg film-coated tablets
Date of the Last Revision of this Leaflet:December 2021
Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The average price of IVABRADINE STADA 7.5 mg FILM-COATED TABLETS in October, 2025 is around 43.27 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for IVABRADINE STADA 7.5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.